Pan J, Li P, Zhou YH, Pan TT, Chen YT, Chu XY. Long-term survival after treatment of gastric cancer with S-1 plus oxaliplatin regimen and sintilimab: A case report. World J Gastrointest Oncol 2025; 17(12): 112853 [DOI: 10.4251/wjgo.v17.i12.112853]
Corresponding Author of This Article
Xiao-Yuan Chu, MD, Department of Oncology, Jinling Hospital, Medical School of Nanjing University, No. 305 Zhongshan East Road, Nanjing 210002, Jiangsu Province, China. chuxiaoyuan0@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Dec 15, 2025 (publication date) through Dec 14, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Pan J, Li P, Zhou YH, Pan TT, Chen YT, Chu XY. Long-term survival after treatment of gastric cancer with S-1 plus oxaliplatin regimen and sintilimab: A case report. World J Gastrointest Oncol 2025; 17(12): 112853 [DOI: 10.4251/wjgo.v17.i12.112853]
Jun Pan, Yi-Tian Chen, Xiao-Yuan Chu, Department of Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, Jiangsu Province, China
Ping Li, Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China
Yu-He Zhou, Ting-Ting Pan, Department of General Medicine, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, Jiangsu Province, China
Co-first authors: Jun Pan and Ping Li.
Co-corresponding authors: Yi-Tian Chen and Xiao-Yuan Chu.
Author contributions: Pan J and Li P drafted the manuscript and made equal contributions as co-first authors; Li P acquired the data; Pan J analyzed and interpreted pathology; Zhou YH and Pan TT analyzed and interpreted the imaging findings; Pan J, Chen YT, and Chu XY contributed to the study conception and design; Chen YT and Chu XY made equal contributions as co-corresponding authors; all authors approved the final version to publish.
Informed consent statement: Written informed consent was obtained from the participant.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Yuan Chu, MD, Department of Oncology, Jinling Hospital, Medical School of Nanjing University, No. 305 Zhongshan East Road, Nanjing 210002, Jiangsu Province, China. chuxiaoyuan0@163.com
Received: August 8, 2025 Revised: September 5, 2025 Accepted: October 20, 2025 Published online: December 15, 2025 Processing time: 126 Days and 2.6 Hours
Abstract
BACKGROUND
Treatment of metastatic gastric cancer (mGC) relies primarily on chemotherapy, which can be effectively combined with immunotherapy. Despite these interventions, overall survival remains suboptimal.
CASE SUMMARY
We report a patient with mGC who received S-1 plus oxaliplatin with sintilimab as first-line therapy, followed by maintenance therapy with S-1 and sintilimab. After 6 months, a partial response was observed, with a 71.7% reduction in the target lesion. After 13 months, the reduction reached 76.3%. Treatment was temporarily paused for 6 months due to a pulmonary infection. Upon re-evaluation 6 months later, the tumor continued to regress, with a 79.4% reduction in the target lesion. The original regimen was then resumed. From diagnosis to date, progression-free survival has reached 23 months.
CONCLUSION
Sintilimab combined with chemotherapy demonstrated improved progression-free survival and warrants further investigation in mGC.
Core Tip: Chemotherapy combined with immunotherapy is the standard first-line treatment for metastatic gastric cancer. However, the first-line median progression-free survival is only about 7 months. This article reports a case of metastatic gastric cancer in which the patient received S-1 plus oxaliplatin regimen with sintilimab, followed by maintenance therapy with S-1 and sintilimab. The patient achieved a partial response and a progression-free survival of 23 months. Moreover, the treatment was temporarily paused for 6 months due to pneumonia. However, upon re-evaluation 6 months later, the tumor continued to regress. This combination therapy has shown encouraging results and warrants further study.
